



Transdermal Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	138	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Transdermal Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Transdermal Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Transdermal Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Transdermal Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Transdermal Drug include Johnson & Johnson, Novartis, Mylan, GSK, Beijing Tide Pharmaceutical, Bayer, UCB Pharma, Teva Pharmaceutical and Nitto Denko, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Transdermal Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/M Pcs) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Transdermal Drug Market by Company

Johnson & Johnson

Novartis

Mylan

GSK

Beijing Tide Pharmaceutical
Bayer
UCB Pharma
Teva Pharmaceutical
Nitto Denko
Mundipharma
Luye Pharma Group
IBSA Group
Hisamitsu Pharmaceutical
Grünenthal
Dr Reddy's Laboratories
Chattem

Transdermal Drug Segment by Type

Methyl Salicylate-based Patch
Diclofenac Patch
Nicotine Transdermal Patch
Lidocaine Patch
Rivastigmine Transdermal Patch
Fentanyl Transdermal Patch
Others

Transdermal Drug Segment by Application

Rx Channel
OTC Channel

Transdermal Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan

Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Transdermal Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Transdermal Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Transdermal Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Transdermal Drug Market Size (2021-2032)
 - 2.2.2 Global Transdermal Drug Sales (2021-2032)
 - 2.2.3 Global Transdermal Drug Market Average Price (2021-2032)
- 2.3 Transdermal Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Methyl Salicylate-based Patch
 - 2.3.3 Diclofenac Patch
 - 2.3.4 Nicotine Transdermal Patch
 - 2.3.5 Lidocaine Patch
 - 2.3.6 Rivastigmine Transdermal Patch
 - 2.3.7 Fentanyl Transdermal Patch
 - 2.3.8 Others
- 2.4 Transdermal Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Rx Channel
 - 2.4.3 OTC Channel

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Transdermal Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Transdermal Drug Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global Transdermal Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Transdermal Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Transdermal Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Transdermal Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Transdermal Drug, Product Type & Application
- 3.8 Global Manufacturers of Transdermal Drug, Established Date
- 3.9 Global Transdermal Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Johnson & Johnson
 - 4.1.1 Johnson & Johnson Company Information
 - 4.1.2 Johnson & Johnson Business Overview
 - 4.1.3 Johnson & Johnson Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

- 4.1.4 Johnson & Johnson Transdermal Drug Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis
 - 4.2.1 Novartis Company Information
 - 4.2.2 Novartis Business Overview
 - 4.2.3 Novartis Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Novartis Transdermal Drug Product Portfolio
 - 4.2.5 Novartis Recent Developments
- 4.3 Mylan
 - 4.3.1 Mylan Company Information
 - 4.3.2 Mylan Business Overview
 - 4.3.3 Mylan Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Mylan Transdermal Drug Product Portfolio
 - 4.3.5 Mylan Recent Developments
- 4.4 GSK
 - 4.4.1 GSK Company Information
 - 4.4.2 GSK Business Overview
 - 4.4.3 GSK Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 GSK Transdermal Drug Product Portfolio
 - 4.4.5 GSK Recent Developments
- 4.5 Beijing Tide Pharmaceutical
 - 4.5.1 Beijing Tide Pharmaceutical Company Information
 - 4.5.2 Beijing Tide Pharmaceutical Business Overview
 - 4.5.3 Beijing Tide Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
 - 4.5.5 Beijing Tide Pharmaceutical Recent Developments
- 4.6 Bayer
 - 4.6.1 Bayer Company Information
 - 4.6.2 Bayer Business Overview
 - 4.6.3 Bayer Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Bayer Transdermal Drug Product Portfolio
 - 4.6.5 Bayer Recent Developments
- 4.7 UCB Pharma
 - 4.7.1 UCB Pharma Company Information
 - 4.7.2 UCB Pharma Business Overview
 - 4.7.3 UCB Pharma Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 UCB Pharma Transdermal Drug Product Portfolio
 - 4.7.5 UCB Pharma Recent Developments
- 4.8 Teva Pharmaceutical
 - 4.8.1 Teva Pharmaceutical Company Information
 - 4.8.2 Teva Pharmaceutical Business Overview
 - 4.8.3 Teva Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Teva Pharmaceutical Transdermal Drug Product Portfolio
 - 4.8.5 Teva Pharmaceutical Recent Developments
- 4.9 Nitto Denko
 - 4.9.1 Nitto Denko Company Information
 - 4.9.2 Nitto Denko Business Overview
 - 4.9.3 Nitto Denko Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.9.4 Nitto Denko Transdermal Drug Product Portfolio

4.9.5 Nitto Denko Recent Developments

4.10 Mundipharma

4.10.1 Mundipharma Company Information

4.10.2 Mundipharma Business Overview

4.10.3 Mundipharma Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.10.4 Mundipharma Transdermal Drug Product Portfolio

4.10.5 Mundipharma Recent Developments

4.11 Luye Pharma Group

4.11.1 Luye Pharma Group Company Information

4.11.2 Luye Pharma Group Business Overview

4.11.3 Luye Pharma Group Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.11.4 Luye Pharma Group Transdermal Drug Product Portfolio

4.11.5 Luye Pharma Group Recent Developments

4.12 IBSA Group

4.12.1 IBSA Group Company Information

4.12.2 IBSA Group Business Overview

4.12.3 IBSA Group Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.12.4 IBSA Group Transdermal Drug Product Portfolio

4.12.5 IBSA Group Recent Developments

4.13 Hisamitsu Pharmaceutical

4.13.1 Hisamitsu Pharmaceutical Company Information

4.13.2 Hisamitsu Pharmaceutical Business Overview

4.13.3 Hisamitsu Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.13.4 Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio

4.13.5 Hisamitsu Pharmaceutical Recent Developments

4.14 Grünenthal

4.14.1 Grünenthal Company Information

4.14.2 Grünenthal Business Overview

4.14.3 Grünenthal Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.14.4 Grünenthal Transdermal Drug Product Portfolio

4.14.5 Grünenthal Recent Developments

4.15 Dr Reddy's Laboratories

4.15.1 Dr Reddy's Laboratories Company Information

4.15.2 Dr Reddy's Laboratories Business Overview

4.15.3 Dr Reddy's Laboratories Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.15.4 Dr Reddy's Laboratories Transdermal Drug Product Portfolio

4.15.5 Dr Reddy's Laboratories Recent Developments

4.16 Chattem

4.16.1 Chattem Company Information

4.16.2 Chattem Business Overview

4.16.3 Chattem Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)

4.16.4 Chattem Transdermal Drug Product Portfolio

4.16.5 Chattem Recent Developments

5 Global Transdermal Drug Market Scenario by Region

5.1 Global Transdermal Drug Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Transdermal Drug Sales by Region: 2021-2032

5.2.1 Global Transdermal Drug Sales by Region: 2021-2026

- 5.2.2 Global Transdermal Drug Sales by Region: 2027-2032
- 5.3 Global Transdermal Drug Revenue by Region: 2021-2032
 - 5.3.1 Global Transdermal Drug Revenue by Region: 2021-2026
 - 5.3.2 Global Transdermal Drug Revenue by Region: 2027-2032
- 5.4 North America Transdermal Drug Market Facts & Figures by Country
 - 5.4.1 North America Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Transdermal Drug Sales by Country (2021-2032)
 - 5.4.3 North America Transdermal Drug Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Transdermal Drug Market Facts & Figures by Country
 - 5.5.1 Europe Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Transdermal Drug Sales by Country (2021-2032)
 - 5.5.3 Europe Transdermal Drug Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Transdermal Drug Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Transdermal Drug Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Transdermal Drug Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Transdermal Drug Market Facts & Figures by Country
 - 5.7.1 South America Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Transdermal Drug Sales by Country (2021-2032)
 - 5.7.3 South America Transdermal Drug Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
- 5.8 Middle East and Africa Transdermal Drug Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Transdermal Drug Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Transdermal Drug Revenue by Country (2021-2032)
 - 5.8.4 Egypt

- 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

- 6.1 Global Transdermal Drug Sales by Type (2021-2032)
 - 6.1.1 Global Transdermal Drug Sales by Type (2021-2032) & (M Pcs)
 - 6.1.2 Global Transdermal Drug Sales Market Share by Type (2021-2032)
 - 6.2 Global Transdermal Drug Revenue by Type (2021-2032)
 - 6.2.1 Global Transdermal Drug Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Transdermal Drug Revenue Market Share by Type (2021-2032)
 - 6.3 Global Transdermal Drug Price by Type (2021-2032)
-

7 Segment by Application

- 7.1 Global Transdermal Drug Sales by Application (2021-2032)
 - 7.1.1 Global Transdermal Drug Sales by Application (2021-2032) & (M Pcs)
 - 7.1.2 Global Transdermal Drug Sales Market Share by Application (2021-2032)
 - 7.2 Global Transdermal Drug Revenue by Application (2021-2032)
 - 7.2.1 Global Transdermal Drug Sales by Application (2021-2032) & (US\$ Million)
 - 7.2.2 Global Transdermal Drug Revenue Market Share by Application (2021-2032)
 - 7.3 Global Transdermal Drug Price by Application (2021-2032)
-

8 Value Chain and Sales Channels Analysis of the Market

- 8.1 Transdermal Drug Value Chain Analysis
 - 8.1.1 Transdermal Drug Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Transdermal Drug Production Mode & Process
 - 8.2 Transdermal Drug Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Transdermal Drug Distributors
 - 8.2.3 Transdermal Drug Customers
-

9 Global Transdermal Drug Analyzing Market Dynamics

- 9.1 Transdermal Drug Industry Trends
 - 9.2 Transdermal Drug Industry Drivers
 - 9.3 Transdermal Drug Industry Opportunities and Challenges
 - 9.4 Transdermal Drug Industry Restraints
-

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Transdermal Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Transdermal Drug Sales (M Pcs) of Manufacturers (2021-2026)
- Table 7: Global Transdermal Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Transdermal Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Transdermal Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Transdermal Drug Average Price (US\$/Pcs) of Manufacturers (2021-2026)
- Table 11: Global Transdermal Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Transdermal Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Transdermal Drug, Product Type & Application
- Table 14: Global Transdermal Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Transdermal Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Johnson & Johnson Company Information
- Table 19: Johnson & Johnson Business Overview
- Table 20: Johnson & Johnson Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 21: Johnson & Johnson Transdermal Drug Product Portfolio
- Table 22: Johnson & Johnson Recent Developments
- Table 23: Novartis Company Information
- Table 24: Novartis Business Overview
- Table 25: Novartis Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 26: Novartis Transdermal Drug Product Portfolio
- Table 27: Novartis Recent Developments
- Table 28: Mylan Company Information
- Table 29: Mylan Business Overview
- Table 30: Mylan Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 31: Mylan Transdermal Drug Product Portfolio
- Table 32: Mylan Recent Developments
- Table 33: GSK Company Information
- Table 34: GSK Business Overview
- Table 35: GSK Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 36: GSK Transdermal Drug Product Portfolio
- Table 37: GSK Recent Developments
- Table 38: Beijing Tide Pharmaceutical Company Information
- Table 39: Beijing Tide Pharmaceutical Business Overview
- Table 40: Beijing Tide Pharmaceutical Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 41: Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
- Table 42: Beijing Tide Pharmaceutical Recent Developments
- Table 43: Bayer Company Information
- Table 44: Bayer Business Overview
- Table 45: Bayer Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 46: Bayer Transdermal Drug Product Portfolio
- Table 47: Bayer Recent Developments
- Table 48: UCB Pharma Company Information
- Table 49: UCB Pharma Business Overview
- Table 50: UCB Pharma Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 51: UCB Pharma Transdermal Drug Product Portfolio
- Table 52: UCB Pharma Recent Developments

- Table 53: Teva Pharmaceutical Company Information
- Table 54: Teva Pharmaceutical Business Overview
- Table 55: Teva Pharmaceutical Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 56: Teva Pharmaceutical Transdermal Drug Product Portfolio
- Table 57: Teva Pharmaceutical Recent Developments
- Table 58: Nitto Denko Company Information
- Table 59: Nitto Denko Business Overview
- Table 60: Nitto Denko Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 61: Nitto Denko Transdermal Drug Product Portfolio
- Table 62: Nitto Denko Recent Developments
- Table 63: Mundipharma Company Information
- Table 64: Mundipharma Business Overview
- Table 65: Mundipharma Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 66: Mundipharma Transdermal Drug Product Portfolio
- Table 67: Mundipharma Recent Developments
- Table 68: Luye Pharma Group Company Information
- Table 69: Luye Pharma Group Business Overview
- Table 70: Luye Pharma Group Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 71: Luye Pharma Group Transdermal Drug Product Portfolio
- Table 72: Luye Pharma Group Recent Developments
- Table 73: IBSA Group Company Information
- Table 74: IBSA Group Business Overview
- Table 75: IBSA Group Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 76: IBSA Group Transdermal Drug Product Portfolio
- Table 77: IBSA Group Recent Developments
- Table 78: Hisamitsu Pharmaceutical Company Information
- Table 79: Hisamitsu Pharmaceutical Business Overview
- Table 80: Hisamitsu Pharmaceutical Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 81: Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio
- Table 82: Hisamitsu Pharmaceutical Recent Developments
- Table 83: Grünenthal Company Information
- Table 84: Grünenthal Business Overview
- Table 85: Grünenthal Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 86: Grünenthal Transdermal Drug Product Portfolio
- Table 87: Grünenthal Recent Developments
- Table 88: Dr Reddy's Laboratories Company Information
- Table 89: Dr Reddy's Laboratories Business Overview
- Table 90: Dr Reddy's Laboratories Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 91: Dr Reddy's Laboratories Transdermal Drug Product Portfolio
- Table 92: Dr Reddy's Laboratories Recent Developments
- Table 93: Chattem Company Information
- Table 94: Chattem Business Overview
- Table 95: Chattem Transdermal Drug Sales (M Pcs), Revenue (US\$ Million), Price (US\$/Pcs) and Gross Margin (2021-2026)
- Table 96: Chattem Transdermal Drug Product Portfolio
- Table 97: Chattem Recent Developments
- Table 98: Global Transdermal Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 99: Global Transdermal Drug Sales by Region (2021-2026) & (M Pcs)
- Table 100: Global Transdermal Drug Sales Market Share by Region (2021-2026)
- Table 101: Global Transdermal Drug Sales by Region (2027-2032) & (M Pcs)
- Table 102: Global Transdermal Drug Sales Market Share by Region (2027-2032)
- Table 103: Global Transdermal Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 104: Global Transdermal Drug Revenue Market Share by Region (2021-2026)
- Table 105: Global Transdermal Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 106: Global Transdermal Drug Revenue Market Share by Region (2027-2032)
- Table 107: North America Transdermal Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: North America Transdermal Drug Sales by Country (2021-2026) & (M Pcs)
- Table 109: North America Transdermal Drug Sales by Country (2027-2032) & (M Pcs)

- Table 110: North America Transdermal Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: North America Transdermal Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Europe Transdermal Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Europe Transdermal Drug Sales by Country (2021-2026) & (M Pcs)
- Table 114: Europe Transdermal Drug Sales by Country (2027-2032) & (M Pcs)
- Table 115: Europe Transdermal Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Europe Transdermal Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: Asia Pacific Transdermal Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 118: Asia Pacific Transdermal Drug Sales by Country (2021-2026) & (M Pcs)
- Table 119: Asia Pacific Transdermal Drug Sales by Country (2027-2032) & (M Pcs)
- Table 120: Asia Pacific Transdermal Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 121: Asia Pacific Transdermal Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 122: South America Transdermal Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 123: South America Transdermal Drug Sales by Country (2021-2026) & (M Pcs)
- Table 124: South America Transdermal Drug Sales by Country (2027-2032) & (M Pcs)
- Table 125: South America Transdermal Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 126: South America Transdermal Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 127: Middle East and Africa Transdermal Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 128: Middle East and Africa Transdermal Drug Sales by Country (2021-2026) & (M Pcs)
- Table 129: Middle East and Africa Transdermal Drug Sales by Country (2027-2032) & (M Pcs)
- Table 130: Middle East and Africa Transdermal Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 131: Middle East and Africa Transdermal Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 132: Global Transdermal Drug Sales by Type (2021-2026) & (M Pcs)
- Table 133: Global Transdermal Drug Sales by Type (2027-2032) & (M Pcs)
- Table 134: Global Transdermal Drug Sales Market Share by Type (2021-2026)
- Table 135: Global Transdermal Drug Sales Market Share by Type (2027-2032)
- Table 136: Global Transdermal Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 137: Global Transdermal Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 138: Global Transdermal Drug Revenue Market Share by Type (2021-2026)
- Table 139: Global Transdermal Drug Revenue Market Share by Type (2027-2032)
- Table 140: Global Transdermal Drug Price by Type (2021-2026) & (US\$/Pcs)
- Table 141: Global Transdermal Drug Price by Type (2027-2032) & (US\$/Pcs)
- Table 142: Global Transdermal Drug Sales by Application (2021-2026) & (M Pcs)
- Table 143: Global Transdermal Drug Sales by Application (2027-2032) & (M Pcs)
- Table 144: Global Transdermal Drug Sales Market Share by Application (2021-2026)
- Table 145: Global Transdermal Drug Sales Market Share by Application (2027-2032)
- Table 146: Global Transdermal Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 147: Global Transdermal Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 148: Global Transdermal Drug Revenue Market Share by Application (2021-2026)
- Table 149: Global Transdermal Drug Revenue Market Share by Application (2027-2032)
- Table 150: Global Transdermal Drug Price by Application (2021-2026) & (US\$/Pcs)
- Table 151: Global Transdermal Drug Price by Application (2027-2032) & (US\$/Pcs)
- Table 152: Key Raw Materials
- Table 153: Raw Materials Key Suppliers
- Table 154: Transdermal Drug Distributors List
- Table 155: Transdermal Drug Customers List
- Table 156: Transdermal Drug Industry Trends
- Table 157: Transdermal Drug Industry Drivers
- Table 158: Transdermal Drug Industry Restraints
- Table 159: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Transdermal Drug Product Image
- Figure 5: Global Transdermal Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Transdermal Drug Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Transdermal Drug Sales (2021-2032) & (M Pcs)
- Figure 8: Global Transdermal Drug Average Price (US\$/Pcs) & (2021-2032)
- Figure 9: Methyl Salicylate-based Patch Product Image
- Figure 10: Diclofenac Patch Product Image
- Figure 11: Nicotine Transdermal Patch Product Image

- Figure 12: Lidocaine Patch Product Image
- Figure 13: Rivastigmine Transdermal Patch Product Image
- Figure 14: Fentanyl Transdermal Patch Product Image
- Figure 15: Others Product Image
- Figure 16: Rx Channel Product Image
- Figure 17: OTC Channel Product Image
- Figure 18: Global Transdermal Drug Revenue Share by Manufacturers in 2025
- Figure 19: Global Manufacturers of Transdermal Drug, Manufacturing Sites & Headquarters
- Figure 20: Global Top 5 and 10 Transdermal Drug Players Market Share by Revenue in 2025
- Figure 21: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: Global Transdermal Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 23: Global Transdermal Drug Sales by Region in 2025
- Figure 24: Global Transdermal Drug Revenue by Region in 2025
- Figure 25: North America Transdermal Drug Market Size by Country in 2025
- Figure 26: North America Transdermal Drug Sales Market Share by Country (2021-2032)
- Figure 27: North America Transdermal Drug Revenue Market Share by Country (2021-2032)
- Figure 28: United States Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Canada Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Mexico Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: Europe Transdermal Drug Market Size by Country in 2025
- Figure 32: Europe Transdermal Drug Sales Market Share by Country (2021-2032)
- Figure 33: Europe Transdermal Drug Revenue Market Share by Country (2021-2032)
- Figure 34: Germany Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: France Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: U.K. Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Italy Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Russia Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Spain Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Netherlands Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Switzerland Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Sweden Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Poland Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Asia Pacific Transdermal Drug Market Size by Country in 2025
- Figure 45: Asia Pacific Transdermal Drug Sales Market Share by Country (2021-2032)
- Figure 46: Asia Pacific Transdermal Drug Revenue Market Share by Country (2021-2032)
- Figure 47: China Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Japan Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: South Korea Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: India Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Australia Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Taiwan Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Southeast Asia Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Southeast Asia Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: South America Transdermal Drug Market Size by Country in 2025
- Figure 56: South America Transdermal Drug Sales Market Share by Country (2021-2032)
- Figure 57: South America Transdermal Drug Revenue Market Share by Country (2021-2032)
- Figure 58: Brazil Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Argentina Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Chile Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: Middle East and Africa Transdermal Drug Market Size by Country in 2025
- Figure 62: Middle East and Africa Transdermal Drug Sales Market Share by Country (2021-2032)
- Figure 63: Middle East and Africa Transdermal Drug Revenue Market Share by Country (2021-2032)
- Figure 64: Egypt Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: South Africa Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Israel Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Türkiye Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: GCC Countries Transdermal Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 69: Global Transdermal Drug Sales Market Share by Type (2021-2032)
- Figure 70: Global Transdermal Drug Revenue Market Share by Type (2021-2032)
- Figure 71: Global Transdermal Drug Price (US\$/Pcs) by Type (2021-2032)
- Figure 72: Global Transdermal Drug Sales Market Share by Application (2021-2032)
- Figure 73: Global Transdermal Drug Revenue Market Share by Application (2021-2032)
- Figure 74: Global Transdermal Drug Price (US\$/Pcs) by Application (2021-2032)
- Figure 75: Transdermal Drug Value Chain
- Figure 76: Transdermal Drug Production Mode & Process

- Figure 77: Direct Comparison with Distribution Share
- Figure 78: Distributors Profiles
- Figure 79: Transdermal Drug Industry Opportunities and Challenges